No recent analyst price targets found for SIGY.
Latest News for SIGY
Oragenics Signs Letter of Intent to License CardioDialysis™ Technology from Sigyn Therapeutics to Target TBI-Induced Systemic Inflammation
The Expected License Agreement Would Position Oragenics as the Only Company with Therapeutic Strategies Targeting TBI-Induced Inflammation on Both Sides of the Blood-Brain Barrier Sarasota, FL and San Diego, CA, May 07, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN) ("Oragenics" or the "Company"), a clinical-stage biopharmaceutical company pioneering neurological therapeutics, and Sigyn Therapeutics,…
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for SIGY.
Senate Trading
No Senate trades found for SIGY.
U.S. House Trading
No House trades found for SIGY.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.